title: [New concepts in management of NMIBC in 2010].
abstract: The aim of this article is to make a synthesis of news headlines concerning the follow-up and the management of non-muscle invasive bladder tumors. The diagnosis and the follow-up of non-muscle invasive bladder are based on flexible cystoscopy associated with urinary cytology. At present time, no molecular marker, and no imaging allows to reduce the rhythm and the modalities of surveillance such as defined by the guidelines. Early cystectomy is the current option for BCG-refractory high risk bladder tumor. Rarely, some conservative options, such as endovesical chemotherapy, could be discussed at an individual level.
authors.affiliation: Service d'Urologie, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 Paris cedex 14, France. gg_pignot@yahoo.fr
authors.forename: G
authors.initials: G
authors.lastname: Pignot
authors.forename: J
authors.initials: J
authors.lastname: Irani
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: V
authors.initials: V
authors.lastname: Ravery
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000175:diagnosis* / Q000628:therapy*; D015653:Cystectomy; D006801:Humans; D017211:Treatment Failure; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine